{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:41:23Z","timestamp":1792057283405,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.yebeh.2025.110753","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:21Z","timestamp":1760140341000},"page":"110753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers"],"prefix":"10.1016","volume":"173","author":[{"given":"Kelly G.","family":"Knupp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Scheffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Sofie","family":"Schoonjans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Lagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Auvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer M.","family":"Zuberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Riney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Nickels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Minh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zhang Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Lothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gil-Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.yebeh.2025.110753_b0005","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International League against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110753_b0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-020-00784-8","article-title":"Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies","volume":"35","author":"Strzelczyk","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2025.110753_b0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.seizure.2022.07.004","article-title":"An Italian consensus on the management of Lennox-Gastaut syndrome","volume":"101","author":"Riva","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110753_b0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/epi4.13075","article-title":"Refining management strategies for Lennox-Gastaut syndrome: updated algorithms and practical approaches","volume":"10","author":"Auvin","year":"2025","journal-title":"Epilepsia Open"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110753_b0025","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/epi4.12998","article-title":"Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice","volume":"9","author":"Wirrell","year":"2024","journal-title":"Epilepsia Open"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110753_b0030","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1528-1167.2006.00616.x","article-title":"Is tolerance to antiepileptic drugs clinically relevant?","volume":"47","author":"Avanzini","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110753_b0035","unstructured":"UCB, Inc. FINTEPLA. Smyrna, GA; December, 2023."},{"key":"10.1016\/j.yebeh.2025.110753_b0040","unstructured":"UCB. Fintepla 2.2 mg\/mL oral solution [summary of product characteristics]. Bruxelles, BE; 2024."},{"key":"10.1016\/j.yebeh.2025.110753_b0045","unstructured":"UCB Pharma. Fintepla\u00ae(fenfluramine hydrochloride) 2.2 mg\/ml oral solution [Australian product information]. Malvern, Australia; November 28 2024."},{"key":"10.1016\/j.yebeh.2025.110753_b0050","unstructured":"UCB Pharma LTD. Fintepla 2.2 mg\/ml oral solution [summary of product characteristics]. Slough, Berkshire; April, 2024."},{"key":"10.1016\/j.yebeh.2025.110753_b0055","unstructured":"UCB Pharma S.A. Fintepla \u00ae Leaflet for the doctor. Ministry of Health Israel, https:\/\/israeldrugs.health.gov.il\/#!\/medDetails\/169%2041%2036976%2099; 2024 [accessed September 16, 2024]."},{"key":"10.1016\/j.yebeh.2025.110753_b0060","unstructured":"Nippon Shinyaku Co. Ltd. Launch of Fintepla\u00ae (fenfluramine) for the treatment of seizures associated with Dravet syndrome in Japan, https:\/\/www.nippon-shinyaku.co.jp\/file\/download.php?file_id=6593; 2022 [accessed February 22, 2023]."},{"key":"10.1016\/j.yebeh.2025.110753_b0065","unstructured":"Nippon Shinyaku Co. Ltd. UCB Japan obtained additional application of fintepla\u00ae(fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome in Japan, https:\/\/www.nippon-shinyaku.co.jp\/file\/download.php?file_id=7484; 2024 [accessed March 28, 2024]."},{"issue":"16","key":"10.1016\/j.yebeh.2025.110753_b0070","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.3390\/ijms22168416","article-title":"An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies","volume":"22","author":"Martin","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110753_b0075","article-title":"In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions","volume":"10","author":"Martin","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110753_b0080","article-title":"In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions","volume":"10","author":"Martin","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110753_b0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110753_b0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17431","article-title":"Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study","volume":"64","author":"Knupp","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110753_b0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.seizure.2022.04.004","article-title":"Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: a network meta-analysis","volume":"99","author":"Devi","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2025.110753_b0100","unstructured":"UCB: Data on file: Periodic safety reports; June 2020-June 2024."},{"key":"10.1016\/j.yebeh.2025.110753_b0105","unstructured":"Bass A, Morita D, Shepherd-Smith J, Zhang Roper R, Tselenti E, Lothe A, et al. Interim results of the US fenfluramine oral solution cardiovascular safety registry study [poster]. Paper presented at: American Epilepsy Society (AES) Annual Meeting, Dec 6-10, 2024, Los Angeles, CA. Poster 1.501."},{"key":"10.1016\/j.yebeh.2025.110753_b0110","unstructured":"Nabbout R, Devinsky O, Lagae L, Scheffer I, Guerrini R, Sullivan J, et al. Fenfluramine efficacy trajectories in placebo or treatment groups from randomized controlled trial to open-label extension [poster]. Paper presented at: American Epilepsy Society (AES) Annual Meeting, Dec 6-10, 2024, Los Angeles, California, USA. Poster 1.408 & Platform F.09."},{"issue":"5","key":"10.1016\/j.yebeh.2025.110753_b0115","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/epi.17866","article-title":"A systematic literature review on the global epidemiology of Dravet syndrome and Lennox-Gastaut syndrome: prevalence, incidence, diagnosis, and mortality","volume":"65","author":"Sullivan","year":"2024","journal-title":"Epilepsia"},{"issue":"17","key":"10.1016\/j.yebeh.2025.110753_b0120","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1212\/WNL.0000000000003685","article-title":"Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"88","author":"Harden","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110753_b0125","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1212\/WNL.0000000000008741","article-title":"Clinical risk factors in SUDEP: a nationwide population-based case-control study","volume":"94","author":"Sveinsson","year":"2020","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.yebeh.2025.110753_b0130","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/epi.17000","article-title":"Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: results of a long-term open-label extension trial","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110753_b0135","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.12561","article-title":"Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3years","volume":"55","author":"Conry","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110753_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.01.002","article-title":"Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial","volume":"121","author":"Ohtsuka","year":"2016","journal-title":"Epilepsy Res"},{"issue":"suppl 1","key":"10.1016\/j.yebeh.2025.110753_b0145","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1111\/j.1528-1157.2000.tb02179.x","article-title":"Topiramate YL Study Group. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial","volume":"41","author":"Glauser","year":"2000","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110753_b0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejpn.2018.09.010","article-title":"Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (\u22651 to <4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303","volume":"23","author":"Arzimanoglou","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110753_b0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13023-023-02626-4","article-title":"The burden of illness in Lennox-Gastaut syndrome: a systematic literature review","volume":"18","author":"Strzelczyk","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110753_b0160","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/epi.17932","article-title":"A comprehensive systematic literature review of the burden of illness of Lennox-Gastaut syndrome on patients, caregivers, and society","volume":"65","author":"Cross","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110753_b0165","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/JMDH.S69300","article-title":"Lennox-Gastaut syndrome: impact on the caregivers and families of patients","volume":"7","author":"Gibson","year":"2014","journal-title":"J Multidiscip Healthc"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110753_b0170","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2009.06.005","article-title":"Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review","volume":"18","author":"Gallop","year":"2009","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110753_b0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2009.10.007","article-title":"Lennox-Gastaut syndrome (LGS): development of conceptual models of health-related quality of life (HRQL) for caregivers and children","volume":"19","author":"Gallop","year":"2010","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110753_b0180","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/epi4.12314","article-title":"Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide study 303","volume":"4","author":"Auvin","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2025.110753_b0185","unstructured":"Auvin S, Scheffer IE, Gil-Nagel A, Lothe A, Polega S, Lagae L, et al. Fenfluramine increases seizure-free days in patients with Lennox-Gastaut syndrome [poster]. Paper presented at: American Epilepsy Society Annual Meeting, Orlando, FL, December 1-5, 20232023."},{"key":"10.1016\/j.yebeh.2025.110753_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108239","article-title":"The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome","volume":"123","author":"Auvin","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2025.110753_b0195","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/epi.17618","article-title":"Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: post hoc analysis of patients receiving cannabidiol in two randomized controlled trials","volume":"64","author":"Auvin","year":"2023","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2025.110753_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2021.09.017","article-title":"Patient and caregiver health state utilities in Lennox-Gastaut syndrome and Dravet syndrome","volume":"43","author":"Lo","year":"2021","journal-title":"Clin Ther"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025004937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025004937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:42:33Z","timestamp":1763746953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505025004937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"alternative-id":["S1525505025004937"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110753","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110753","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 UCB Pharma S.A. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110753"}}